{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:38:24Z","timestamp":1790401104034,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abrocitinib has demonstrated long\u2010term efficacy (48\u2009weeks) and safety (~4\u2009years) in adults and adolescents with moderate\u2010to\u2010severe atopic dermatitis (AD). This analysis evaluated abrocitinib efficacy in adolescents through 112\u2009weeks, and safety of up to 4.6\u2009years of exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were from adolescents in JADE MONO\u20101 (NCT03349060), MONO\u20102 (NCT03575871), TEEN (NCT03796676), REGIMEN (NCT03627767; safety analysis only), and the ongoing phase 3 extension trial, EXTEND (NCT03422822; data cutoff: September 5, 2022). Efficacy assessments included proportions of patients achieving an Investigator's Global Assessment score of 0 or 1 (IGA 0\/1) and \u2265\u200975%\/\u2265\u200990% improvement in Eczema Area and Severity Index (EASI\u201075\/\u201090). Treatment\u2010emergent adverse events (TEAEs) and AEs of special interest were reported as incidence rate\/100 patient\u2010years. A substudy of JADE TEEN assessed immune response to vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Efficacy was assessed in 170 and 187 patients in the abrocitinib 200\u2010mg and 100\u2010mg arms, respectively; median exposure was 971.0 and 899.0\u2009days. At Week 112, comparable proportions of patients treated with abrocitinib (200, 100\u2009mg) achieved EASI\u201075 (85%, 83%), EASI\u201090 (62%, 60%), and IGA 0\/1 (57%, 57%). Safety was assessed in 289 and 201 patients in the abrocitinib 200\u2010 and 100\u2010mg arms, respectively; median exposure was 882.0 and 863.0\u2009days. Incidence rates were numerically higher with abrocitinib 200\u2009mg versus 100\u2009mg, with overlapping confidence intervals for serious TEAEs (IR [95% CI]; 5.47 [3.69\u20137.80] vs. 3.45 [1.89\u20135.80]) and TEAEs leading to discontinuation (6.78 [4.80\u20139.31] vs. 5.39 [3.38\u20138.16]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Efficacy and safety results support long\u2010term abrocitinib use in adolescent patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      Identifiers NCT03349060, NCT03575871, NCT03796676, NCT03627767, NCT03422822.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.16512","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:50:16Z","timestamp":1741711816000},"page":"2213-2224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate\u2010to\u2010Severe Atopic Dermatitis"],"prefix":"10.1111","volume":"80","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"University of California San Diego and Rady Children's Hospital\u2010San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2044","authenticated-orcid":false,"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[{"name":"Clinical Medicine, School of Medicine Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[{"name":"University Hospital Augsburg  Augsburg Germany"},{"name":"Ludwig Maximilian University  Munich Germany"},{"name":"Comprehensive Center for Inflammation Medicine University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6629-9100","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Barbarot","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Nantes\u2010H\u00f4tel Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bangert","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-5353","authenticated-orcid":false,"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"},{"name":"Department of Pediatrics Perelman School of Medicine, University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Selfridge","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Fan","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Watkins","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Koppensteiner","sequence":"additional","affiliation":[{"name":"Pfizer Corporation Austria GmbH  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16892"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.12.020"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.038"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19280"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00869-w"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","unstructured":"A.Paller L. F.Eichenfield M. J.Cork et\u00a0al. \u201cIntegrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate\u2010to\u2010Severe Atopic Dermatitis from the Phase 3 Clinical Trial Program \u201dPresented at the American Academy of Dermatology (AAD) Annual Meeting March 25\u201329 2022; Boston Massachusetts.","DOI":"10.1016\/j.jaad.2022.06.323"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20887"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"e_1_2_10_16_1","unstructured":"A.Egeberg A.Wollenberg T.Bieber A. R.Lemeshow andS.Vyas \u201cIncidence of Venous Thromboembolic Events and Atherosclerotic Cardiovascular Disease Risk Factors in Adolescents and Adults with Atopic Dermatitis in Denmark: A Population\u2010Based Cohort Study.\u201dPresented at: the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; December 10 2023; Virtual."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277469"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.08.007"},{"key":"e_1_2_10_19_1","unstructured":"Centers for Disease Control and Prevention \u201cU.S. Cancer Statistics Data Visualizations Tool Based on 2022 Submission Data (1999\u20132020) \u201daccessed November 12 2024 www.cdc.gov\/cancer\/dataviz."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060907"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.09.026"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.09.015"},{"key":"e_1_2_10_23_1","unstructured":"Centers for Disease Control and Prevention \u201cDiptheria Tetanus and Pertussis Vaccine Recommendations \u201daccessed November 12 2024 https:\/\/www.cdc.gov\/vaccines\/vpd\/dtap\u2010tdap\u2010td\/hcp\/recommendations.html."},{"key":"e_1_2_10_24_1","volume-title":"Epidemiology and Prevention of Vaccine\u2010Preventable Diseases","author":"Havers F. P.","year":"2021"},{"key":"e_1_2_10_25_1","unstructured":"\u201cCibinqo (Abrocitinib) 100 mg Film\u2010Coated Tablets \u201dSummary of Product Characteristics. Pfizer Europe MA EEIG April 5 2024."},{"key":"e_1_2_10_26_1","unstructured":"\u201cCibinqo (Abrocitinib) Tablets for Oral Use \u201dPrescribing Information. Pfizer Labs December 14 2023."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200866"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.16512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.16512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.16512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T14:55:50Z","timestamp":1771167350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.16512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/all.16512"],"URL":"https:\/\/doi.org\/10.1111\/all.16512","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}